ADMA vs TRVI: Which Stock Is the Better Buy?
ADMA Biologics, Inc. and Trevi Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ADMA vs TRVI, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| ADMA Biologics, Inc. (ADMA) | Trevi Therapeutics, Inc. (TRVI) | |
|---|---|---|
| Market cap | $1.9B | $2.0B |
| Revenue (latest FY) | $510.17M | $0 |
| Net income (latest FY) | $146.93M | $-42.76M |
| Revenue growth (5y CAGR) | 64.6% | — |
| Net margin | 28.8% | — |
| Return on equity | 30.8% | -23.3% |
| P/E ratio | 12.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ADMA vs TRVI breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ADMA's full financials → Open TRVI's full financials →More comparisons
Frequently asked questions
Which is bigger, ADMA or TRVI?
Trevi Therapeutics, Inc. is larger by market capitalization — $2.0B versus $1.9B.
Which grows faster, ADMA or TRVI?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.